Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab Phase 2b in RA with Inadequate Response to TNF Inhibitors
NCT02015520Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Jun 2012
- Primary completion
- Jun 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of clazakizumab in rheumatoid arthritis (RA), sponsored by CSL Limited. Started Jun 2012; status: completed.
02
Drugs
clazakizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02015520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015520.